0001209191-20-054613.txt : 20201013
0001209191-20-054613.hdr.sgml : 20201013
20201013155421
ACCESSION NUMBER: 0001209191-20-054613
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201012
FILED AS OF DATE: 20201013
DATE AS OF CHANGE: 20201013
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McDevitt Damien
CENTRAL INDEX KEY: 0001742277
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38137
FILM NUMBER: 201236231
MAIL ADDRESS:
STREET 1: C/O IONIS PHARMACEUTICALS, INC.
STREET 2: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AKCEA THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001662524
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472608175
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 22 BOSTON WHARF RD
STREET 2: 9TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 617-207-0202
MAIL ADDRESS:
STREET 1: 22 BOSTON WHARF RD
STREET 2: 9TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-12
1
0001662524
AKCEA THERAPEUTICS, INC.
AKCA
0001742277
McDevitt Damien
C/O AKCEA THERAPEUTICS, INC.
22 BOSTON WHARF ROAD, 9TH FLOOR
BOSTON
MA
02210
1
1
0
0
Chief Executive Officer
Common Stock
2020-10-12
4
U
0
242978
18.15
D
0
D
Stock Option (right to buy)
12.76
2020-10-12
4
D
0
120000
5.39
D
2030-03-18
Common Stock
120000
0
D
Stock Option (right to buy)
12.76
2020-10-12
4
D
0
200000
5.39
D
2030-03-18
Common Stock
200000
0
D
This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $646,800.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.
This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $1,078,000.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.
/s/ Joshua F. Patterson, Attorney-in-Fact
2020-10-12